Many systemically effective drugs such as cyclosporin A are ineffective topically because of their poor penetration into skin. To surmount this problem, we conjugated a heptamer of arginine to cyclosporin A through a pH-sensitive linker to produce R7–CsA. In contrast to unmodified cyclosporin A, which fails to penetrate skin, topically applied R7–CsA was efficiently transported into cells in mouse and human skin. R7–CsA reached dermal T lymphocytes and inhibited cutaneous inflammation. These data establish a general strategy for enhancing delivery of poorly absorbed drugs across tissue barriers and provide a new topical approach to the treatment of inflammatory skin disorders.
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Roberts, M.S. Targeted drug delivery to the skin and deeper tissues: role of physiology, solute structure and disease. Clin. Exp. Pharmacol. Physiol. 24, 874–879 (1997).
Ranade, V.V. Drug delivery systems. 6. Transdermal drug delivery. J. Clin. Pharmacol. 31, 401–418 ( 1991).
Hadgraft, J. & Pugh, W.J. The selection and design of topical and transdermal agents: a review. J. Invest. Dermatol. Symp. Proc. 3, 131–135 ( 1998).
Berti, J.J. & Lipsky, J.J. Transcutaneous drug delivery: a practical review. Mayo Clinic Proc. 70, 581–586 (1995).
Bach, M. & Lippold, B.C. Percutaneous penetration enhancement and its quantification. Eur. J. Pharm. Biopharm. 46 , 1–13 (1998).
Doering, T. et al. Sphingolipid activator proteins are required for epidermal permeability barrier formation. J. Biol. Chem. 274, 11038–11045 (1999).
Ghadially, R., Brown, B.E., Sequeira-Martin, S.M., Feingold, K.R. & Elias, P.M. The aged epidermal permeability barrier. Structural, functional, and lipid biochemical abnormalities in humans and a senescent murine model. J. Clin. Invest. 95, 2281–2290 (1995).
Proksch, E., Holleran, W.M., Menon, G.K., Elias, P.M. & Feingold, K.R. Barrier function regulates epidermal lipid and DNA synthesis. Br. J. Dermatol. 128, 473–482 (1993).
Sowden, J.M. et al. Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 338, 137–140 (1991).
Berth-Jones, J. et al. Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis. Br. J. Dermatol. 136, 76–81 (1997).
Naeyaert, J.M. et al. Cyclosporin in atopic dermatitis: review of the literature and outline of a Belgian consensus. Dermatology 198 , 145–152 (1999).
Ho, V.C. et al. Intermittent short courses of cyclosporin (Neoral(R)) for psoriasis unresponsive to topical therapy: a 1-year multicentre, randomized study. The PISCES Study Group. Br. J. Dermatol. 141, 283–291 (1999).
Koo, J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporin, Neoral and Sandimmun, in patients with severe psoriasis. OLP302 Study Group. Br. J. Dermatol. 139, 88–95 (1998).
Berth-Jones, J. & Voorhees, J.J. Consensus conference on cyclosporin A microemulsion for psoriasis, June 1996. Br J Dermatol 135, 775–777 (1996).
Powles, A.V. et al. Renal function after 10 years' treatment with cyclosporin for psoriasis. Br. J. Dermatol. 138, 443 –449 (1998).
Furlanut, M., Baraldo, M., Galla, F., Marzocchi, V. & Pea, F. Cyclosporin nephrotoxicity in relation to its metabolism in psoriasis. Pharmacol. Res. 33, 349–352 (1996).
Sieg, P., Von Domarus, H., Von Zitzewitz, V., Iven, H. & Farber, L. Topical cyclosporin in oral lichen planus: a controlled, randomized, prospective trial. Br. J. Dermatol. 132, 790–794 ( 1995).
Duncan, J.I., Wakeel, R.A., Winfield, A.J., Ormerod, A.D. & Thomson, A.W. Immunomodulation of psoriasis with a topical cyclosporin A formulation. Acta Derm. Venereol. 73, 84–87 ( 1993).
Surber, C., Itin, P., Buchner, S. & Maibach, H.I. Effect of a new topical cyclosporin formulation on human allergic contact dermatitis. Contact Dermatitis 26, 116–119 (1992).
De Rie, M.A., Meinardi, M.M. & Bos, J.D. Lack of efficacy of topical cyclosporin A in atopic dermatitis and allergic contact dermatitis. Acta Derm. Venereol. 71, 452–454 ( 1991).
Gilhar, A., Pillar, T. & Etzioni, A. Topical cyclosporin A in alopecia areata. Acta Derm. Venereol. 69, 252–253 (1989).
de Prost, Y. et al. Placebo-controlled trial of topical cyclosporin in severe alopecia areata. Lancet 2, 803– 804 (1986).
Mrowietz, U. The enigma of cyclosporin A treatment for psoriasis: systemic efficacy versus topical non-responsiveness. A review. Acta Derm. Venereol. 72, 321–326 (1992).
Schmook, F.P., Stutz, A. & Reinhardt, J. Penetration of Sandimmune (cyclosporin A) in rat skin in vitro. Effects of penetration enhancers and solvents . Skin Pharmacol. 6, 116– 124 (1993).
Oikarinen, A., Haapasaari, K.M., Sutinen, M. & Tasanen, K. The molecular basis of glucocorticoid-induced skin atrophy: topical glucocorticoid apparently decreases both collagen synthesis and the corresponding collagen mRNA level in human skin in vivo. Br. J. Dermatol. 139, 1106–1110 (1998).
Gilbertson, E.O., Spellman, M.C., Piacquadio, D.J. & Mulford, M.I. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J. Am. Acad. Dermatol. 38, 318–321 ( 1998).
Miyachi, Y. Adrenal axis suppression caused by a small dose of a potent topical corticosteroid . Arch. Dermatol. 118, 451– 452 (1982).
Baumann, L. & Kerdel, F. in Topical Glucocorticoids 2713–2717 (McGraw-Hill, New York, 1999).
Kim, D.T. et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV tat peptide. J. Immunol. 159 , 1666–1668 (1997).
Nagahara, H. et al. Transduction of full-length TAT fusion proteins into mammalian cells: TAT-p27Kip1 induces cell migration. Nature Med. 4, 1449–1452 (1998).
Derossi, D., Joliot, A.H., Chassaing, G. & Prochiantz, A. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269, 10444– 10450 (1994).
Schwarze, S.R., Hruska, K.A. & Dowdy, S.F. Protein transduction: unrestricted delivery into all cells?. Trends Cell Biol. 10, 290 –295 (2000).
Klemm, J.D., Schreiber, S.L. & Crabtree, G.R. Dimerization as a regulatory mechanism in signal transduction . Annu. Rev. Immunol. 16, 569– 592 (1998).
Handschumacher, R.E., Harding, M.W., Rice, J., Drugge, R.J. & Speicher, D.W. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science 226, 544–547 (1984).
Wiskocil, R., Weiss, A., Imboden, J., Kamin-Lewis, R. & Stobo, J. Activation of a human T cell line: a two-stimulus requirement in the pretranslational events involved in the coordinate expression of interleukin 2 and gamma-interferon genes. J. Immunol. 134, 1599–1603 (1985).
Choate, K.A., Medalie, D.A., Morgan, J.R. & Khavari, P.A. Corrective gene transfer in the human skin disorder lamellar ichthyosis. Nature Med. 2, 1263–1267 (1996).
Prochiantz, A. Messenger proteins: homeoproteins, TAT and others. Curr. Opin. Cell Biol. 12, 400–406 ( 2000).
Simpson, J., Zhang, Q., Ozaeta, P. & Aboleneen, H. A specific method for the measurement of cyclosporin A in human whole blood by liquid chromatography-tandem mass spectrometry. Ther. Drug Monit. 20, 294–300 (1998).
About this article
Cite this article
Rothbard, J., Garlington, S., Lin, Q. et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat Med 6, 1253–1257 (2000). https://doi.org/10.1038/81359
Chemistry – A European Journal (2021)
Drug Delivery and Translational Research (2021)
Proceedings of the National Academy of Sciences (2021)
Portable bioluminescent platform for in vivo monitoring of biological processes in non-transgenic animals
Nature Communications (2021)